Warfarin is highly effective in preventing strokes in people with atrial fibrillation (AF), but has its limitations. Only half of patients who could benefit actually receive warfarin, resulting in an estimated 7000 avoidable strokes each year. There are now three NICE-approved novel oral anticoagulant drugs (NOACs) licensed for stroke prevention in non-valvular AF. NOACs are easy to use and can provide a safe and effective alternative to warfarin in selected patients who can adhere to the treatment regimen.
